CoChat

Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium

Triggle, C. R., Ding, H. · 2017 · Acta Physiologica
Cited by 100

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Metformin, a synthetic dimethyl biguanide, has been in clinical use for over 55 years, and today is considered the first-choice drug for the treatment of type 2 diabetes used by an estimated 125 million people worldwide. Metformin is orally effective, not metabolized, excreted unchanged by the kidney, relatively free of side effects and well tolerated by the majority of patients. Of importance is that the United Kingdom Prospective Diabetes Study 20-year study of type 2 diabetics, completed in 1998, compared patients treated with insulin, sulfonylureas and metformin and concluded that metformin provided vascular protective actions. Cardiovascular disease is the primary basis for the high morbidity and mortality that is associated with diabetes and that metformin proved to be protective resulted in a dramatic increase in its use. The vascular protective actions of metformin are thought to be secondary to the antihyperglycaemic effects of metformin that are mediated via activation of AMP kinase and subsequent inhibition of hepatic gluconeogenesis, fatty acid oxidation as well as an insulin sensitizing action in striated muscle and adipose tissue. As reflected by a number of clinical studies, patients treated with metformin also have improvement in endothelial function as measured by the use of plethysmography and measurement of flow-mediated vasodilatation. These data as well as data from animal studies are supportive that metformin has a direct protective action on the vascular endothelium. In this review article, we discuss the pharmacology of metformin and critique the literature as to its cellular sites and mechanism(s) of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apha.12644

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 80

  1. Allen, 1960, Dimethyl biguanidine dans le traitement du diabete sucre, Rev Francaise d'Endocrinol Clin, 2, 1
  2. Arunachalam, 2010, SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol, Biochem Biophys Res Commun, 393, 66, 10.1016/j.bbrc.2010.01.080 · DOI · Paper page
  3. Arunachalam, 2014b, Micro RNA-34a mediates impaired angiogenesis in diabetes: Role of SIRT1 and metformin, FASEB J, 28, 1051.2, 10.1096/fasebj.28.1_supplement.1051.2 · DOI
  4. Arunachalam, 2015a, MicroRNA signature and cardiovascular dysfunction, J Cardiovasc Pharmacol, 65, 419, 10.1097/FJC.0000000000000178 · DOI
  5. Arunachalam, 2015b, Molecular interplay between microRNA-34a and sirtuin1 in hyperglycaemia-mediated impaired angiogenesis in endothelial cells: Effects of metformin, J Pharmacol Exp Ther
  6. Badrick, 2014, Diabetes and cancer: 5 years into the recent controversy, Eur J Cancer, 50, 2119, 10.1016/j.ejca.2014.04.032 · DOI · Paper page
  7. Bailey, 2004, Metformin: its botanical background, Pract Diabetes Int, 21, 115, 10.1002/pdi.606 · DOI · Paper page
  8. Ben Sahra, 2010, The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells, Autophagy, 6, 670, 10.4161/auto.6.5.12434 · DOI · Paper page
  9. Berkowitz, 2014, Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study, JAMA Intern Med, 174, 1955, 10.1001/jamainternmed.2014.5294 · DOI · Paper page
  10. Blandino, 2012, Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC, Nat Commun, 29, 865, 10.1038/ncomms1859 · DOI · Paper page
  11. Bommer, 2007, p53-mediated activation of miRNA34 candidate tumor-suppressor genes, Curr Biol, 17, 1298, 10.1016/j.cub.2007.06.068 · DOI · Paper page
  12. Bordone, 2005, Calorie restriction, SIRT1 and metabolism: understanding longevity, Nat Rev Mol Cell Biol, 6, 298, 10.1038/nrm1616 · DOI · Paper page
  13. Brownlee, 2001, Biochemisty and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a · DOI · Paper page
  14. Chang, 2002, Regulation of lifespan by histone deacetylase, Ageing Res Rev, 1, 313, 10.1016/S1568-1637(02)00003-X · DOI · Paper page
  15. Cheang, 2014, Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway, Arterioscler Thromb Vasc Biol, 34, 830, 10.1161/ATVBAHA.113.301938 · DOI · Paper page
  16. Chen, 1999, AMP-activated protein kinase phosphorylation of endothelial NO synthase, FEBS Lett, 443, 285, 10.1016/S0014-5793(98)01705-0 · DOI · Paper page
  17. Chen, 2010, Shear stress, SIRT1, and vascular homeostasis, Proc NatL Acad Sci USA, 107, 10268, 10.1073/pnas.1003833107 · DOI · Paper page
  18. Davis, 2006, Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, Diabetes, 55, 496, 10.2337/diabetes.55.02.06.db05-1064 · DOI · Paper page
  19. Deichmann, 1986, What is there that is not poison? A study of the Third Defense by Paracelsus, Arch Toxicol, 58, 207, 10.1007/BF00297107 · DOI
  20. Diabetes Control and Complications Trial Research Group, 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
  21. Ding, 2010, Endothelial dysfunction in diabetes: multiple targets for treatment, Pflugers Arch, 459, 977, 10.1007/s00424-010-0807-3 · DOI
  22. Dobrina, 1983, Metabolic properties of freshly isolated bovine endothelial cells, Biochim Biophys Acta, 762, 295, 10.1016/0167-4889(83)90084-8 · DOI
  23. Dolinsky, 2011, Calorie restriction and resveratrol in cardiovascular health and disease, Biochim Biophys Acta, 1812, 1477, 10.1016/j.bbadis.2011.06.010 · DOI · Paper page
  24. Dumortier, 2013, MicroRNAs and metabolism crosstalk in energy homeostasis, Cell Metab, 18, 312, 10.1016/j.cmet.2013.06.004 · DOI · Paper page
  25. Enkhjargal, 2014, Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice, Arterioscler Thromb Vasc Biol, 34, 1505, 10.1161/ATVBAHA.114.303735 · DOI
  26. Faubert, 2013, AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo, Cell Metab, 17, 113, 10.1016/j.cmet.2012.12.001 · DOI · Paper page
  27. Grundy, 2003, Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association, Circulation, 105, 2231, 10.1161/01.CIR.0000013952.86046.DD · DOI · Paper page
  28. Hadden, 2005, Goat's rue - French lilac - Italian fitch -Spanish sainfoin: gallega officinalis and metformin: The Edinburgh connection, J R Coll Physicians Edinb, 35, 258, 10.1177/1478271520053503010 · DOI
  29. Hemmingsen, 2012, Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses, BMJ, 344, e1771, 10.1136/bmj.e1771 · DOI · Paper page
  30. Herzig, 2001, CREB regulates hepatic gluconeogenesis through the coactivator PGC-1, Nature, 413, 179, 10.1038/35093131 · DOI · Paper page
  31. Hou, 2010, Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway, Biochem Biophys Res Commun, 396, 199, 10.1016/j.bbrc.2010.04.017 · DOI · Paper page
  32. Ibáñez, 2006, Metformin treatment to prevent early puberty in girls with precocious pubarche, J Clin Endocrinol Metab, 91, 2888, 10.1210/jc.2006-0336 · DOI · Paper page
  33. Ito, 2010, MicroRNA-34a regulation of endothelial senescence, Biochem Biophys Res Commun, 398, 735, 10.1016/j.bbrc.2010.07.012 · DOI · Paper page
  34. Jansson, 1996, The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM, Diabetes Care, 19, 160, 10.2337/diacare.19.2.160 · DOI · Paper page
  35. Katakam, 2000, Metformin improves vascular function in insulin-resistant rats, Hypertension, 35, 108, 10.1161/01.HYP.35.1.108 · DOI · Paper page
  36. Kato, 2015, Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor, Biochem Biophys Res Commun, 461, 115, 10.1016/j.bbrc.2015.03.178 · DOI
  37. Kim, 2008, SIRT1: roles in ageing and cancer, BMB Rep, 41, 751, 10.5483/BMBRep.2008.41.11.751 · DOI · Paper page
  38. Langman, 2006, Toxicology: then and now, Clin Biochem, 39, 498, 10.1016/j.clinbiochem.2006.03.004 · DOI
  39. Lee, 2010, AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner, J Biol Chem, 285, 32182, 10.1074/jbc.M110.134890 · DOI · Paper page
  40. Lin, 2014, Ghrelin receptor regulates appetite and satiety during aging in mice by regulating meal frequency and portion size but not total food intake, J Nutr, 144, 1349, 10.3945/jn.114.191171 · DOI
  41. Liu, 2014a, Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK, Proc Natl Acad Sci U S A, 111, E435, 10.1073/pnas.1311121111 · DOI · Paper page
  42. Ludvigsson, 2014, The latest pharmacotherapy options for type 1 diabetes, Expert Opin Pharmacother, 15, 37, 10.1517/14656566.2014.855197 · DOI
  43. Marfella, 1996, Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients, Diabetes Care, 9, 934, 10.2337/diacare.19.9.934 · DOI · Paper page
  44. Memmott, 2010, Metformin prevents tobacco carcinogen-induced lung tumorigenesis, Cancer Prev Res (Phila), 3, 1066, 10.1158/1940-6207.CAPR-10-0055 · DOI · Paper page
  45. Ota, 2007, Sirt1 modulates premature senescence-like phenotype in human endothelial cells, J Mol Cell Cardiol, 43, 571, 10.1016/j.yjmcc.2007.08.008 · DOI · Paper page
  46. Ota, 2008, Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells, Arterioscler Thromb Vasc Biol, 28, 1634, 10.1161/ATVBAHA.108.164368 · DOI · Paper page
  47. Ouchi, 2005, AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle, Circ Res, 96, 838, 10.1161/01.RES.0000163633.10240.3b · DOI · Paper page
  48. Pernicova, 2014, Metformin-mode of action and clinical implications for diabetes and cancer, Nat Rev Endocrinol, 10, 143, 10.1038/nrendo.2013.256 · DOI · Paper page
  49. Potente, 2008, NO targets SIRT1: a novel signaling network in endothelial senescence, Arterioscler Thromb Vasc Biol, 28, 1577, 10.1161/ATVBAHA.108.173682 · DOI
  50. Qin, 2012, Role of microRNAs in endothelial inflammation and senescence, Mol Biol Rep, 39, 4509, 10.1007/s11033-011-1241-0 · DOI
  51. Rocha, 2011, Metformin amplifies chemotherapy-induced AMPK-activation and antitumoral growth, Clin Cancer Res, 17, 3993, 10.1158/1078-0432.CCR-10-2243 · DOI · Paper page
  52. Sakamoto, 2006, Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1, Am J Physiol Endocrinol Metab, 290, E780, 10.1152/ajpendo.00443.2005 · DOI · Paper page
  53. Salpeter, 2003, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst Rev, 2, CD002967
  54. Sambol, 1996, Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus, J Clin Pharmacol, 36, 1012, 10.1177/009127009603601105 · DOI · Paper page
  55. Schäfer, 1980, Guanidines and biguanides, Pharmacol Ther, 8, 275, 10.1016/0163-7258(80)90049-2 · DOI
  56. Scheen, 1996, Clinical pharmacokinetics of metformin, Clin Pharmacokinet, 30, 359, 10.2165/00003088-199630050-00003 · DOI · Paper page
  57. Shu, 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics, Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275 · DOI · Paper page
  58. Sirtoli, 1978, Dispositin of metformin (NN-dimethylbiguanide) in man, Clin Pharmacol Ther, 24, 683, 10.1002/cpt1978246683 · DOI · Paper page
  59. Stein, 2010, SIRT1 reduces endothelial activation without affecting vascular function in ApoE−/− mice, Aging (Albany, NY), 2, 353, 10.18632/aging.100162 · DOI · Paper page
  60. Sterne, 1957, Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.), Maroc Med, 36, 1295
  61. Suarez, 2009, MicroRNAs as novel regulators of angiogenesis, Circ Res, 104, 442, 10.1161/CIRCRESAHA.108.191270 · DOI · Paper page
  62. Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies, Diabetes Care, 35, 2665, 10.2337/dc12-0788 · DOI · Paper page
  63. Tabuchi, 2012, MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression, Clin Sci (Lond), 123, 161, 10.1042/CS20110563 · DOI · Paper page
  64. Tan, 2011, Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes, Cancer, 117, 5103, 10.1002/cncr.26151 · DOI · Paper page
  65. Towler, 2007, AMP-activated protein kinase in metabolic control and insulin signaling, Circ Res, 100, 328, 10.1161/01.RES.0000256090.42690.05 · DOI · Paper page
  66. Triggle, 2010, A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS, J Am Soc Hypertens, 4, 102, 10.1016/j.jash.2010.02.004 · DOI
  67. Triggle, 2014, Cardiovascular impact of drugs used in the treatment of diabetes, Ther Adv Chronic Dis, 5, 245, 10.1177/2040622314546125 · DOI · Paper page
  68. Triggle, 2014, Metformin: Targets SIRT1 and microRNAs in microvascular endothelial cells, J Vasc Res, 51, 37
  69. Tucker, 1981, Metformin kinetics in healthy subjects and in patients with diabetes mellitus, Br J Clin Pharmacol, 12, 235, 10.1111/j.1365-2125.1981.tb01206.x · DOI · Paper page
  70. Werner, 1921, The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively, J Chem Soc Trans, 121, 1790, 10.1039/CT9222101790 · DOI · Paper page
  71. Wu, 2012, Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo, PLoS One, 7, e35508, 10.1371/journal.pone.0035508 · DOI · Paper page
  72. Xu, 2005, Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex, Am J Physiol, 289, F1040
  73. Yamakuchi, 2008, miR-34a repression of SIRT1 regulates apoptosis, Proc Natl Acad Sci U S A, 105, 13421, 10.1073/pnas.0801613105 · DOI · Paper page
  74. Yue, 2008, Effect of genetic variation in the organic cation transporter, Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275 · DOI · Paper page
  75. Yun, 2005, Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma, J Biol Chem, 280, 9963, 10.1074/jbc.M412994200 · DOI · Paper page
  76. Zampetaki, 2012, MicroRNAs in vascular and metabolic disease, Circ Res, 110, 508, 10.1161/CIRCRESAHA.111.247445 · DOI · Paper page
  77. Zhang, 2000, High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells, J Biol Chem, 275, 40042, 10.1074/jbc.M007505200 · DOI · Paper page
  78. Zhang, 2013, Metformin reduces vascular endothelial dysfunction caused by an acute glucose load in patients with hypertension, Blood Press, 22, 106, 10.3109/08037051.2012.732761 · DOI
  79. Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505 · DOI · Paper page
  80. Zhu, 2015, Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies, Diabetologia, 58, 900, 10.1007/s00125-015-3510-2 · DOI · Paper page

Cited by

See all 100

Metadata

Authors
Triggle, C. R., & Ding, H.
Venue
Acta Physiologica
Publisher
Wiley
Published
2016-01-13
Volume
219
Issue
1
Pages
138-151
ISSN
1748-1708 (ISSN-L)
OpenAlex
W2217461794
Cited by
100
References
46
FWCI
2.96
Type
journal article
Language
en
Open access
closed
Licence
Funders
  • NPRP (4-910-3-244, 5-149-3-040)
  • Qatar National Research Fund
  • Qatar Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.